The BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA).
The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range.
The acquisition of MBS perfectly complements the company’s current product portfolio and coincides with its commercial team expansion, giving the company important new technology and products.
Dr Joseph Chandler, Founder and President of MBS, said: “The BBI Group was aware of our reputation in the market for high quality antibody products services. They currently have no capacity for antibody development and manufacture and, with a waiting customer base for this, MBS is a logical addition to their business. They are on an ambitious growth plan and I know that MBS will be a key part of their future plans.”